BioArctic AB Overview
Pro stress-test →BioArctic AB (publ) is a Swedish research-based biopharma company focusing on disease-modifying treatments for neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease and ALS. The company leverages proprietary expertise in blood-brain barrier penetration to develop monoclonal antibodies that address critical unmet medical needs in CNS disorders.
Strategic Profile
Pro stress-test →The company has strategically important global partnerships with Eisai (Alzheimer's) and AbbVie (Parkinson's), with a project portfolio combining fully funded partnerships and innovative in-house projects with significant market potential. Under an agreement with Eisai, BioArctic has marketing rights to lecanemab in the Nordic region and is building a commercial organization to prepare for potential launch.
Competitive Landscape
Pro stress-test →BioArctic competes in the neurodegenerative disease treatment space dominated by Eisai (Leqembi co-developer), Eli Lilly (Donanemab), and Roche/AC Immune. The company's competitive advantage rests on its BrainTransporter™ technology platform for CNS drug delivery and partnerships with global leaders managing commercial risk.
Industry Context
BioArctic AB operates in Biopharmaceuticals / Neurology / Central Nervous System Disorders.
Key facts
Founded: 2000 · Headquarters: Stockholm, Sweden · Employees: 122 · Revenue: $203M · Market cap: $3.02B